ixazomib (Ninlaro®)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Multiple myeloma

All of the following must be met as a condition for coverage:

  • Treatment of multiple myeloma (in combination with lenalidomide and dexamethasone) in patients who have received at least 1 prior therapy

This Medication is Not Approvable for the following condition(s).

  • Any condition not listed above as an approved indication

Dosing:

  • 4 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone)
  • Continue until disease progression or unacceptably toxicity
Approval:
 
One Year
 

 

Last review date: July 25, 2016